BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 33327806)

  • 21. Design, synthesis and biological evaluation of harmine derivatives as potent GSK-3β/DYRK1A dual inhibitors for the treatment of Alzheimer's disease.
    Liu W; Liu X; Tian L; Gao Y; Liu W; Chen H; Jiang X; Xu Z; Ding H; Zhao Q
    Eur J Med Chem; 2021 Oct; 222():113554. PubMed ID: 34098466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Design and Synthesis of New
    Farghaly TA; Pashameah RA; Bayazeed A; Al-Soliemy AM; Alsaedi AMR; Harras MF
    Med Chem; 2024; 20(1):63-77. PubMed ID: 37723960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mechanistic selectivity investigation and 2D-QSAR study of some new antiproliferative pyrazoles and pyrazolopyridines as potential CDK2 inhibitors.
    Hassan GS; Georgey HH; Mohammed EZ; George RF; Mahmoud WR; Omar FA
    Eur J Med Chem; 2021 Jun; 218():113389. PubMed ID: 33784602
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Discovery of New Pyrazolopyridine, Furopyridine, and Pyridine Derivatives as CDK2 Inhibitors: Design, Synthesis, Docking Studies, and Anti-Proliferative Activity.
    Abdel-Rahman AA; Shaban AKF; Nassar IF; El-Kady DS; Ismail NSM; Mahmoud SF; Awad HM; El-Sayed WA
    Molecules; 2021 Jun; 26(13):. PubMed ID: 34206976
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel pyrazolopyrimidines: Synthesis, in vitro cytotoxic activity and mechanistic investigation.
    Hassan GS; Abdel Rahman DE; Nissan YM; Abdelmajeed EA; Abdelghany TM
    Eur J Med Chem; 2017 Sep; 138():565-576. PubMed ID: 28704759
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
    El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
    Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery of novel pyrimidine-based benzothiazole derivatives as potent cyclin-dependent kinase 2 inhibitors with anticancer activity.
    Diao PC; Lin WY; Jian XE; Li YH; You WW; Zhao PL
    Eur J Med Chem; 2019 Oct; 179():196-207. PubMed ID: 31254921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis of Coumarin Derivatives as Versatile Scaffolds for GSK-3β Enzyme Inhibition.
    Francisco CS; Javarini CL; de S Barcelos I; Morais PAB; de Paula H; de S Borges W; Neto ÁC; Lacerda V
    Curr Top Med Chem; 2020; 20(2):153-160. PubMed ID: 31648640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design, green synthesis, molecular docking and anticancer evaluations of diazepam bearing sulfonamide moieties as VEGFR-2 inhibitors.
    Saleh NM; El-Gaby MSA; El-Adl K; Abd El-Sattar NEA
    Bioorg Chem; 2020 Nov; 104():104350. PubMed ID: 33142416
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis, molecular docking and cytotoxic evaluation of novel 2-furybenzimidazoles as VEGFR-2 inhibitors.
    Abdullaziz MA; Abdel-Mohsen HT; El Kerdawy AM; Ragab FAF; Ali MM; Abu-Bakr SM; Girgis AS; El Diwani HI
    Eur J Med Chem; 2017 Aug; 136():315-329. PubMed ID: 28505536
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis, anticancer and antimicrobial evaluation of new benzofuran based derivatives: PI3K inhibition, quorum sensing and molecular modeling study.
    El-Khouly OA; Henen MA; El-Sayed MA; Shabaan MI; El-Messery SM
    Bioorg Med Chem; 2021 Feb; 31():115976. PubMed ID: 33388654
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design, synthesis, anticancer evaluation, molecular docking and cell cycle analysis of 3-methyl-4,7-dihydropyrazolo[1,5-a]pyrimidine derivatives as potent histone lysine demethylases (KDM) inhibitors and apoptosis inducers.
    Metwally NH; Mohamed MS; Ragb EA
    Bioorg Chem; 2019 Jul; 88():102929. PubMed ID: 31015179
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Discovery of novel β-carboline derivatives as selective AChE inhibitors with GSK-3β inhibitory property for the treatment of Alzheimer's disease.
    Liu W; Liu X; Liu W; Gao Y; Wu L; Huang Y; Chen H; Li D; Zhou L; Wang N; Xu Z; Jiang X; Zhao Q
    Eur J Med Chem; 2022 Feb; 229():114095. PubMed ID: 34995924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New cell cycle checkpoint pathways regulators with 2-Oxo-indoline scaffold as potential anticancer agents: Design, synthesis, biological activities and in silico studies.
    Abd El-Wahab HAA; Mansour HS; Ali AM; El-Awady R; Aboul-Fadl T
    Bioorg Chem; 2022 Mar; 120():105622. PubMed ID: 35091290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synthesis of a new series of pyrazolo[1,5-a]pyrimidines as CDK2 inhibitors and anti-leukemia.
    Almehmadi SJ; Alsaedi AMR; Harras MF; Farghaly TA
    Bioorg Chem; 2021 Dec; 117():105431. PubMed ID: 34688130
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design, synthesis, and molecular docking study of 3H-imidazole[4,5-c]pyridine derivatives as CDK2 inhibitors.
    Wu YZ; Ying HZ; Xu L; Cheng G; Chen J; Hu YZ; Liu T; Dong XW
    Arch Pharm (Weinheim); 2018 Jun; 351(6):e1700381. PubMed ID: 29708285
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and biological evaluation of novel 5,6-dihydropyrimido[4,5-f]quinazoline derivatives as potent CDK2 inhibitors.
    Hu X; Zhao H; Wang Y; Liu Z; Feng B; Tang C
    Bioorg Med Chem Lett; 2018 Nov; 28(20):3385-3390. PubMed ID: 30197029
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utilization of cyanopyridine in design and synthesis of first-in-class anticancer dual acting PIM-1 kinase/HDAC inhibitors.
    Bass AKA; Nageeb EM; El-Zoghbi MS; Mohamed MFA; Badr M; Abuo-Rahma GEA
    Bioorg Chem; 2022 Feb; 119():105564. PubMed ID: 34959179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and analysis of antiproliferative and apoptosis-inducing activities of nitrile derivatives containing a benzofuran scaffold: EGFR inhibition assay and molecular modelling study.
    Fares S; Selim KB; Goda FE; El-Sayed MAA; AlSaif NA; Hefnawy MM; Abdel-Aziz AA; El-Azab AS
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1488-1499. PubMed ID: 34227457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design and molecular modeling of novel P38α MAPK inhibitors targeting breast cancer, synthesized from oxygen heterocyclic natural compounds.
    Abdelhafez OM; Ahmed EY; Abdel Latif NA; Arafa RK; Abd Elmageed ZY; Ali HI
    Bioorg Med Chem; 2019 Apr; 27(7):1308-1319. PubMed ID: 30792101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.